AtomVie Global Radiopharma

AtomVie in its spinout and Series A Financing


AtomVie Global Radiopharma




Emerging and High Growth Companies

Date Closed

August 2022


Pharmaceuticals and Life Sciences

Lead Office



On August 24, 2022, AtomVie Global Radiopharma Inc. announced it had completed its series A funding with Avego Management, LLC, an investment firm specializing in healthcare. With this funding, AtomVie plans to expand their production capability by building a new state-of-the-art facility.

AtomVie is a spinout from the Centre for Probe Development and Commercialization. They are a leading global CDMO (Contract Development and Manufacturing Organization) that develops, manufactures, and distributes radiopharmaceuticals.

Osler, Hoskin & Harcourt LLP advised AtomVie with a team consisting of David Jamieson, Andrew Irwin, Jeremy Lin, Darren Gill (Emerging and High Growth Companies), Nathaniel Lipkus (Intellectual Property), Kelly O’Ferrall (Employment and Labour), Simon Hodgett, Mike Jankowski (Technology), and Matthew Ritchie (Real Estate).